- 631 views
How will antibacterial treatments perform commercially' Our new pharma report examines this fundamental but increasingly-important marketOver 130 tables, charts, graphs, figures included.Our latest ...
How will antibacterial treatments perform commercially' Our new pharma report examines this fundamental but increasingly-important marketOver 130 tables, charts, graphs, figures included.Our latest report examines the prospects for antibacterial treatments worldwide from 2009 to 2024, including detailed sales forecasts for leading products in that sector. The global anti-infectives market generated revenues of $79bn for the 12 months to the second-quarter of 2009, of which the antibacterial market accounted for $37bn. How will this market perform from 2010 onwards' Our original forecasts and qualitative analyses will show you how the antibacterial sector will fare, pointing out the most-exciting and fast-growing areas.This market segment contained three blockbuster drugs in 2009: J&J's Levaquin, Tazocin from Wyeth and Pfizer's Zyvox. However, the market for antibacterial treatments is entering a crucial phase, with important brands facing patent expiry or having already past that mark, with ensuing generic competition. How is the industry dealing with this combined threat and opportunity' What will happen in future years' The World Antibacterial Treatments Market 2010-2024 explains.The market for systemic antibiotics is set to become increasingly dynamic over the forecast period (2010-2024). The key factors influencing this market segment include:' Aging populations' Increased infection rates in both developed and developing nations' Increasing bacterial resistance' Increasing numbers of immuno-compromised patients' Increases in organ transplantation.This report will specifically analyse world markets for the following classes of antibacterial agent:' Cephalosporins' Penicillins' Fluoroquinolones' Macrolides' Carbapenems' Miscellaneous agents (including tetracyclines, aminoglycosides, glycopeptides and sulphonamides).There are many infection-related disorders and cross links with other disease areas. Some infections will become increasingly challenging to treat, with a growing number of pathogens becoming resistant to existing therapies. Current R&D - including new classes of antibiotics - offers promise for the development of safer, more-effective and affordable treatments. This report will provide you with valuable information there.Detailed analysis of the world antibacterial treatments marketThe World Antibacterial Treatments Market 2010-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 130 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.Research interviews from our surveyThis report contains full original interviews with the following relevant experts:1) Dr John Philpott-Howard, Consultant Physician & Senior Lecturer in Medical Microbiology, Sub-Dean for Undergraduate Medicine, King's College London School of Medicine, UK2) Dr Eileen C. McIntyre, Cubist Pharmaceuticals Inc., Lexington, MA, USAWhy you should buy The World Antibacterial Treatments Market 2010-2024In this new report, you will receive the following benefits in particular:' You will assess the value of the world antibacterial treatments market and its principal market segments from 2009 to 2024' You will understand commercial prospects for the leading products, with sales forecasts from 2009 to 2024 and detailed discussions' Your will see the potential for generic penetration into the market from 2009 to 2024' You will see which marketed drugs have the potential to become blockbusters from 2009 to 2024.' You will review the most-exciting pipeline developments in the sector' You will receive discussion of unmet therapeutic needs
- Total Views
- Views on SlideShare
- Embed Views